Sep 28, 2025 11:13 AM Eastern Daylight Time Share New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – Additional Analyses Reinforce Vutrisiran's Safety and Efficacy Profile as a Monotherapy and Illustrate Consistent Benefit from Treatment with Vutrisiran ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) returned 13.29% (net of fees) in the quarter, compared to the Russell Midcap Growth Index’s 18.20% return. Stock selection in the Industrials and Information Technology sectors negatively impacted the performance, while holdings in the Financials sector contributed. In addition, please check the fund ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Styl ...

Question-and-Answer SessionWell, maybe just to start off, would you like to share some opening thoughts on Alnylam for those who are a little bit less familiar?Jeffrey PoultonCFO & Executive VP Sure. We're a company that pioneered a new class of medicine called RNAi therapeutics. It's been a 20-plus-year journey for the company. There was a lot of work, probably for the first 10-plus years around delivery. But once the company figured out delivery, there's really been a steady cadence of progress. And wher ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) FY Conference September 23, 2025 08:00 AM ET Company ParticipantsJeff Poulton - CFOConference Call ParticipantsWilliam Pickering - Senior AnalystWilliam PickeringGood morning, everyone. My name is Will Pickering. I'm Bernstein's U.S. senior analyst for U.S. biotech. Very pleased to be kicking off our 2025 Healthcare Forum with Alnylam Pharmaceuticals. We have Jeff Poulton here, CFO. Jeff, thanks so much for joining us.Jeff PoultonThanks for having us. Good to be here. ...

专利诉讼解决 - Moderna与Alnylam Pharmaceuticals就COVID-19疫苗递送技术专利诉讼达成和解协议[2] - Alnylam指控Moderna疫苗递送技术侵犯其专利权利[2] - 双方根据周四提交的法院文件达成解决方案[2]

Healthcare payment concept with stethoscope and big money US dollar.gettyMost Wall Street “suits” are allergic to dividend cuts. These spreadsheet jockeys sooooo lack imagination. They prefer linear trends—up and to the right.Dividend growers model nicely. Payout “resets” (cuts!) do not. So, there is often a knee-jerk reaction from analysts to sell every divvie slash they see.Same goes for most individual income investors. These vanilla beans sold BlackRock Health Sciences Term Trust (BMEZ) late last week w ...

Accessibility StatementSkip Navigation Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the ...

Market Analysis by covering: Alnylam Pharmaceuticals Inc, DexCom Inc, Veeva Systems Inc Class A, BlackRock Health Sciences Trust II. Read 's Market Analysis on Investing.com ...